{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:41:47Z","timestamp":1773798107414,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N. A."],"award-info":[{"award-number":["N. A."]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N. A."],"award-info":[{"award-number":["N. A."]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N. A."],"award-info":[{"award-number":["N. A."]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N. A."],"award-info":[{"award-number":["N. A."]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N. A."],"award-info":[{"award-number":["N. A."]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-59186-1","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T09:53:55Z","timestamp":1731318835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03733717","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mingyuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Ziti-Ljajic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Semiond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"59186_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. JAMA. 327, 464\u2013477 (2022).","journal-title":"JAMA."},{"key":"59186_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14737140.2021.1837627","volume":"21","author":"M Jullien","year":"2021","unstructured":"Jullien, M., Touzeau, C. & Moreau, P. Monoclonal antibodies as an addition to current myeloma therapy strategies. Expert Rev. Anticancer Ther. 21, 33\u201343 (2021).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"59186_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","volume":"9","author":"T Martin","year":"2019","unstructured":"Martin, T. et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 9, 41 (2019).","journal-title":"Blood Cancer J."},{"key":"59186_CR4","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1038\/s41375-020-0857-2","volume":"34","author":"J Mikhael","year":"2020","unstructured":"Mikhael, J. et al. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed\/refractory multiple myeloma. Leukemia 34, 3298\u20133309 (2020).","journal-title":"Leukemia"},{"key":"59186_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood.2020008209","volume":"137","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood 137, 1154\u20131165 (2021).","journal-title":"Blood"},{"key":"59186_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","volume":"11","author":"J Mikhael","year":"2021","unstructured":"Mikhael, J. et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 11, 89 (2021).","journal-title":"Blood Cancer J."},{"key":"59186_CR7","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1111\/cas.14657","volume":"111","author":"K Sunami","year":"2020","unstructured":"Sunami, K. et al. Isatuximab monotherapy in relapsed\/refractory multiple myeloma: A Japanese, multicenter, phase 1\/2, safety and efficacy study. Cancer Sci. 111, 4526\u20134539 (2020).","journal-title":"Cancer Sci."},{"key":"59186_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani, S. Z. et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 128, 37\u201344 (2016).","journal-title":"Blood."},{"key":"59186_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial, S. et al. Daratumumab monotherapy in patients with treatment refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet. 387, 1551\u20131560 (2016).","journal-title":"Lancet."},{"key":"59186_CR10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet. 394, 2096\u20132107 (2019).","journal-title":"Lancet."},{"key":"59186_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial. Lancet Oncol. 22, 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"key":"59186_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos, M. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study. Lancet. 396, 186\u2013197 (2020).","journal-title":"Lancet."},{"key":"59186_CR13","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau, P. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet. 397, 2361\u20132371 (2021).","journal-title":"Lancet."},{"key":"59186_CR14","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert, J. et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 20, 4574\u20134583 (2014).","journal-title":"Clin Cancer Res."},{"key":"59186_CR15","first-page":"S180 (abstr P-2","volume":"13","author":"T Cai","year":"2013","unstructured":"Cai, T., Wetzel, M., Nicolazzi, C., Vallee, F. & Deckert, J. Preclinical characterisation of SAR650984, a humanized anti-CD38 antibody, for the treatment of multiple myeloma. Clin. Lymphoma Myeloma Leuk. 13, S180 (abstr P-288) (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"59186_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 30, 399\u2013408 (2016).","journal-title":"Leukemia."},{"key":"59186_CR17","unstructured":"Sarclisa. Prescribing information. Sanofi; July 2022. Accessed 15 May 2023. https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf (2022)."},{"key":"59186_CR18","unstructured":"European Medicines Agency. Sarclisa, INN-Ixatuximab. Summary of product characteristics. Accessed 15 May 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf (2021)."},{"key":"59186_CR19","unstructured":"SARCLISA\u00ae (isatuximab). Prescribing Information. Nishi Shinjuku, Tokyo, 2021. Accessed 15 May 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_4291454A1021_1_02 (2021)."},{"key":"59186_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"59186_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.4155\/bio.13.145","volume":"5","author":"KJ Fraley","year":"2013","unstructured":"Fraley, K. J. et al. The Gyrolab immunoassay system: A platform for automated bioanalysis and rapid sample turnaround. Bioanalysis. 5, 1765\u20131774 (2013).","journal-title":"Bioanalysis."},{"key":"59186_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1208\/s12248-013-9552-9","volume":"16","author":"S Dudal","year":"2014","unstructured":"Dudal, S. et al. Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 16, 194\u2013205 (2014).","journal-title":"AAPS J."},{"key":"59186_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jim.2015.08.002","volume":"426","author":"J Zoghbi","year":"2015","unstructured":"Zoghbi, J., Xu, Y., Grabert, R., Theobald, V. & Richards, S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J. Immunol. Methods 426, 62\u201369 (2015).","journal-title":"J. Immunol. Methods"},{"key":"59186_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","volume":"24","author":"H Myler","year":"2021","unstructured":"Myler, H. et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 24, 4 (2021).","journal-title":"AAPS J."},{"key":"59186_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"59186_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/psp4.12789","volume":"11","author":"F Rachedi","year":"2022","unstructured":"Rachedi, F. et al. Exposure-response analyses for selection\/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide\/dexamethasone treatment in patients with multiple myeloma. CPT Pharmacomet. Syst. Pharmacol. 11, 766\u2013777 (2022).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"59186_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40262-014-0159-9","volume":"53","author":"AA Othman","year":"2014","unstructured":"Othman, A. A., Tran, J. Q., Tang, M. T. & Dutta, S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: Integrated analysis of intravenous and subcutaneous, single-and multiple-dose administration. Clin. Pharmacokinet. 53, 907\u2013918 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"59186_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.dmpk.2015.12.003","volume":"31","author":"W Honma","year":"2016","unstructured":"Honma, W., Gautier, A., Paule, I., Yamaguchi, M. & Lowe, P. J. Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion. Drug Metab Pharmacokinet. 31, 173\u2013184 (2016).","journal-title":"Drug Metab Pharmacokinet."},{"key":"59186_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s12325-018-0815-9","volume":"35","author":"XS Xu","year":"2018","unstructured":"Xu, X. S. et al. Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv. Ther. 35, 1859\u20131872 (2018).","journal-title":"Adv. Ther."},{"key":"59186_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antib8040056","volume":"8","author":"VA Thomas","year":"2019","unstructured":"Thomas, V. A. & Balthasar, J. P. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies (Basel) 8, 56 (2019).","journal-title":"Antibodies (Basel)"},{"key":"59186_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","volume":"101","author":"X Leleu","year":"2022","unstructured":"Leleu, X. et al. Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: Differential mechanisms of action and recent clinical trial outcomes. Ann. Hematol. 101, 2123\u20132137 (2022).","journal-title":"Ann. Hematol."},{"key":"59186_CR32","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","volume":"21","author":"J Lu","year":"2021","unstructured":"Lu, J. et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: Phase 3 LEPUS (MMY3009) study. Clin. Lymphoma Myeloma Leuk. 21, e699\u2013e709 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"59186_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.clml.2022.04.005","volume":"22","author":"K Sunami","year":"2022","unstructured":"Sunami, K. et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in East Asian patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis. Clin. Lymphoma Myeloma Leuk. 22, 751\u2013761 (2022).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"59186_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12185-022-03378-w","volume":"116","author":"K Kim","year":"2022","unstructured":"Kim, K. et al. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. Int. J. Hematol. 116, 553\u2013562 (2022).","journal-title":"Int. J. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59186-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59186-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59186-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:15:36Z","timestamp":1731672936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59186-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["59186"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-59186-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS, HJ, XQ, FD, and JQ: nothing to disclose. YL, ZF, SZ-L, DS, and LL are employed by Sanofi and may hold stock and\/or stock options. LQ: consulting for AstraZeneca, Beigene, Xi'an Janssen, Pfizer; Speaker Bureau participation for AstraZeneca, Beigene, Xi'an Janssen, Pfizer, Roche, and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27550"}}